<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04189250</url>
  </required_header>
  <id_info>
    <org_study_id>COMP_aCO_oCO</org_study_id>
    <nct_id>NCT04189250</nct_id>
  </id_info>
  <brief_title>Comparison of the Automatized and the Optimized Carbon Monoxid Rebreathing Protocol</brief_title>
  <official_title>Comparison of the Automatized and the Optimized Carbon Monoxid Rebreathing Protocol Determining Hemoglobinmass With Capillary and Venous Blood Sampling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Federal Institute of Sport Magglingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Federal Institute of Sport Magglingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is the comparison of two measurement protocols determining hemoglobin
      mass with two different blood sampling strategies.Both protocols are based on the principle
      of the carbonmonoxid (CO) rebreathing method. During this measurement, CO is inhaled for a
      specific time period by the subject in a closed circuit and it is used as a marker to tag
      circulating hemoglobin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The optimized CO rebreathing protocol (oCO) will be compared against the automatized CO
      rebreathing protocol (aCO). Although theses two protocols using the same method, they show
      some relevant differences.

      The oCO use a 2 minutes rebreathing period in a seated position and capillary blood is taken.
      The aCO use a 10 minutes rebreathing period in a supine position and venous blood samples are
      taken.

      It is essential to know to what extent the aCO with capillary or venous blood sampling with
      different rebreathing time and position compared to oCO will influence the provided
      hemoglobin mass values. It is important to ensure the comparability of formely hemoglobinmass
      data measured using oCO with hemoglobinmass data measured using aCO for scientific research.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of two CO rebreathing protocols (aCO and oCO)</measure>
    <time_frame>During data collection (3 months)</time_frame>
    <description>The aim is to assess the confidence interval of aCO with a ten min rebreathing period in supine position compared to oCO with a two min seated rebreathing period. The mean difference in hemoglobin mass will be determined, using the aCO and oCO.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of capillary and venous bloodsampling</measure>
    <time_frame>During data collection (3 months)</time_frame>
    <description>The aim is to compare capillary and venous blood samples collected simultaneously during aCO. The goal is to determine, if the site of blood sampling alters the measured carboxy-hemoglobin and hence the calculated hemoglobin mass.
The outcome will be the confidence interval of mean difference measured with capillary and venous blood sampling.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reliability of aCO and oCO</measure>
    <time_frame>During data collection (3 months)</time_frame>
    <description>The aim is the determination of the reliability of aCO and oCO by implementing double measurements for both protocols. The coefficient of variation (CV) of hemoglobin mass measured for aCO and oCO will be a further outcome of the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Hemoglobins</condition>
  <arm_group>
    <arm_group_label>Optimized carbonmonoxid rebreathing protocol (oCO)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 min rebreathing period seated position capillary blood sampling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Automatized carbonmonoxide rebreathing protocol (aCO)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 minutes rebreathing period supine position venous blood sampling</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Automatized carbonmonoxide rebreathing machine - OpCO Detalo instruments</intervention_name>
    <description>The automatized protocol (aCO) will be conducted with automated system OpCO of Detalo instruments. The intended use of the OpCO Detalo instrument is to quantify hemoglobin mass in human. The principle behind the machine is the widely used CO rebreathing technique. The machine applies automatically the desired CO dose to the patient to determine hemoglobin mass. The Detalo Instruments OpCO is certified conform to the following CE norms: Electromagentic compabilitiy: DIN EN 60601-1-2 and electrical Safety test: LVD 2014/35/EU.</description>
    <arm_group_label>Automatized carbonmonoxide rebreathing protocol (aCO)</arm_group_label>
    <arm_group_label>Optimized carbonmonoxid rebreathing protocol (oCO)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 or higher

          -  healthy (self-reported)

          -  women and men

        Exclusion Criteria:

          -  smoker

          -  implementation of high altitude training six weeks before and during the study

          -  sickness before and during the study

          -  blood donation 6 weeks before and during the study

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Wehrlin, Dr. scient., MSc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swiss Federal Institute of Sport Magglingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jon Wehrlin, Dr. scient., MSc.</last_name>
    <phone>+41 58 467 61 25</phone>
    <email>jon.wehrlin@baspo.admin.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katja Kellenberger, MSc</last_name>
    <phone>+41584661803</phone>
    <phone_ext>+41584661803</phone_ext>
    <email>katja.kellenberger@baspo.admin.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Swiss Federal Instistiution of Sport</name>
      <address>
        <city>Magglingen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon Wehrlin</last_name>
      <phone>+58 4676125</phone>
      <email>jon.wehrlin@baspo.admin.ch</email>
    </contact>
    <contact_backup>
      <last_name>Katja Kellenberger</last_name>
      <phone>+41792782109</phone>
      <email>katja.kellenberger@baspo.admin.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Jon Wehrlin, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Schmidt W, Prommer N. The optimised CO-rebreathing method: a new tool to determine total haemoglobin mass routinely. Eur J Appl Physiol. 2005 Dec;95(5-6):486-95. Epub 2005 Oct 13.</citation>
    <PMID>16222540</PMID>
  </reference>
  <reference>
    <citation>Fagoni N, Breenfeldt Andersen A, Oberholzer L, Haider T, Meinild Lundby AK, Lundby C. Reliability and validity of non-invasive determined haemoglobin mass and blood volumes. Clin Physiol Funct Imaging. 2018 Mar;38(2):240-245. doi: 10.1111/cpf.12406. Epub 2017 Jan 30.</citation>
    <PMID>28135764</PMID>
  </reference>
  <reference>
    <citation>Siebenmann C, Keiser S, Robach P, Lundby C. CORP: The assessment of total hemoglobin mass by carbon monoxide rebreathing. J Appl Physiol (1985). 2017 Sep 1;123(3):645-654. doi: 10.1152/japplphysiol.00185.2017. Epub 2017 Jun 29. Review.</citation>
    <PMID>28663373</PMID>
  </reference>
  <reference>
    <citation>Steiner T, Wehrlin JP. Comparability of haemoglobin mass measured with different carbon monoxide-based rebreathing procedures and calculations. Scand J Clin Lab Invest. 2011 Feb;71(1):19-29. doi: 10.3109/00365513.2010.534174. Epub 2010 Nov 23.</citation>
    <PMID>21091271</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 3, 2019</study_first_submitted>
  <study_first_submitted_qc>December 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2019</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbon Monoxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

